Glenview Capital, which ran a consent-solicitation contest that unseated the entire board of directors at HMA in August, says it intends to fully support HMA’s deal to sell itself to rival Community Health System, where Glenview is also the biggest shareholder.

That has shares of both stocks trading higher Wednesday after months of uncertainty on the fate of the deal and amid one of the more interesting activist situations of the year.

HMA is up 6% to $13.27 while Community Health was up 2.2% to $43.25. That rise has HMA trading right around the deal’s value, which includes $10.50 in cash and 0.06942 share of Community Health.

Glenview shies away from public activism and has consistently declared itself a “suggestivist” instead of an activist, saying at one point it was the Mr. Spock of activists and not like a William Wallace of Braveheart fame.

Still, in this case, Glenview put up a slate for the board and rejected several compromise attempts by HMA, including one to add the entire dissident slate while retaining some HMA directors. HMA’s deal to sell itself, done at a discount to the prior close, didn’t end the campaign. In August, shareholders supported the hedge fund’s slate and the new board pledged a review of the sale.

Today, as HMA announces a third-quarter loss of nearly $96.6 million compared with a year-ago profit of $41 million, Glenview and the rest of the board express their support to get on with the sale. The board says in a release it has concluded with the help of its bankers that the deal, about $7.6 billion including debt, provides “maximum value” for holders. Glenview, in its own separate statement, says much the same.

“We are disappointed to learn of the weakness at HMA as reflected in their Q3 results, which we believe reflects on the stewardship of the old Board and prior senior management,” the hedge fund says in a statement. “Based upon this comprehensive review and transparent disclosure of financial and operating conditions that is being made today, Glenview confirms its intention to vote its shares in favor of the CHS proposal, which we believe represents full and fair value for HMA.”

For what it’s worth, Glenview also notes it supports the deal as Community Health’s largest holder too.

And Glenview takes a bit of a victory lap, saying the results of the review and the new board, and really the entire saga, “reinforces the importance of shareholder engagement.”